Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Raised to “Hold” at Wall Street Zen

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on BCYC. Jefferies Financial Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Bicycle Therapeutics in a report on Thursday. Zacks Research cut shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Needham & Company LLC reduced their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Hold” and an average target price of $13.57.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $3.66 on Friday. Bicycle Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.48. The business has a 50 day moving average price of $3.83 and a two-hundred day moving average price of $4.58.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.25. The company had revenue of $34.06 million during the quarter, compared to the consensus estimate of $12.22 million. Bicycle Therapeutics had a negative net margin of 169.75% and a negative return on equity of 25.40%. As a group, sell-side analysts expect that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. raised its stake in Bicycle Therapeutics by 15.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock valued at $85,000 after purchasing an additional 3,000 shares during the period. Portland Investment Counsel Inc. purchased a new stake in Bicycle Therapeutics in the 2nd quarter worth approximately $64,000. Marquette Asset Management LLC purchased a new position in Bicycle Therapeutics in the second quarter valued at about $309,000. FNY Investment Advisers LLC lifted its stake in Bicycle Therapeutics by 247.4% in the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock valued at $111,000 after acquiring an additional 18,693 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after buying an additional 6,447 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.